Compare AstraZeneca plc (AZN) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Riot Platforms Inc — how do they compare? AstraZeneca plc trades at $168.5 (market cap $253.13B), while Riot Platforms Inc trades at $20.07 (market cap $7.64B). The key difference: AstraZeneca plc is far larger — about 33.1× Riot Platforms Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| AZN | RIOT | |
|---|---|---|
Market Cap | $253.13B | $7.64B |
Sector | Health | Technology |
52-Week High | $209.48 | $28.67 |
52-Week Low | $137.44 | $11.03 |
Enterprise Value | $279.37B | $8.31B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
RIOT stock trades at $20.19, down 3.7% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $663.18 million in 2025, with a negative net income margin of -132.76%, though revenue reached $647.44 million. Analyst consensus remains strongly bullish with a $27.86 price target, supported by 17 buy ratings. Recent news highlights volatility amid broader crypto stock trends and a strategic pivot toward high-performance computing.
The outlook is mixed: strong analyst support and a strategic shift to data centers offer upside, but persistent losses, negative cash flow from operations, and sensitivity to Bitcoin market swings pose significant risks. Investors should weigh the high valuation multiples against the company's unprofitability and execution challenges in its expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
